It is suggested that anti-CTLA-4 may be considered a more effective treatment regimen due to its interference with the initial steps of T cell activation, whereas anti-PD-L1 therapy specifically targets tumor-specific T cell populations [26]. The gene discussed is CD274; the disease is neoplasm.